Evidence map›Paper›PMID 31045551›Full record

ArticleTechnology and health care : official journal of the European Society for Engineering and Medicine2019

Gefitinib-coated balloon inhibits the excessive hyperplasia of intima after vascular injuries through PI3K/AKT pathway.

Fen Tang, Maojun Liu, Ou Zeng, Wenting Tan, Junrong Long, Shengquan Liu, Jun Yang, Chun Chu

Open access · bronzeAbstract read
In one paragraph

Article in Technology and health care : official journal of the European Society for Engineering and Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023
    Review
  3. Article
  4. Article
  5. Preventive Effect and Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fen TangDepartment of Cardiology, the First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Maojun LiuDepartment of Cardiology, the First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Ou ZengDepartment of Cardiology, the First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Wenting TanDepartment of Cardiology, the First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Junrong Long
Shengquan LiuDepartment of Cardiology, the First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Jun YangDepartment of Cardiology, the First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Chun ChuDepartment of Pharmacy, the Second Affiliated Hospital of University of South China, Hengyang, Hunan, China.
First Affiliated Hospital of University of South China · CNUniversity of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the effect of gefitinib-coated balloon suppressive action on the excessive hyperplasia of intima after balloon injury of common carotid artery in rats and on the PI3K/AKT signal pathway.

methodsMTT method and the expression of Bcl-2 and Caspase-3 proteins were detected in vitro; Adult SD rats were randomly split into 5 groups, namely sham group, model group, low-dosage gefitinib-coated balloon group, high-dosage gefitinib-coated balloon group, and paclitaxel-coated balloon group. The intimal proliferation of arteries, PCNA, P-AKT and PI3K protein expression, the cell apoptosis, expression of MMP9, TGFβ and IL6 mRNA were measured by hematoxylin and eosin (H&E) staining, immunohistochemistry, TUNEL staining, and RT-qPCR.

resultsAt the same time and concentration, Gefitinib suppressed the proliferation of smooth muscle cell more significantly than paclitaxel. Bcl-2 and Caspase-3 in vascular smooth muscle and endothelial cells (VSMC, EC) were significantly down-regulated and up-regulated after the cells were treated with gefitinib and paclitaxel. In gefitinib- and paclitaxel-coated balloon groups, significant up-regulations were found in the area of lumen. Furthermore, the expression of PCNA suggested that all coated balloons could suppress the excessive proliferation of smooth muscle cells in the hyperplastic intima compared with the control group. In gefitinib- and paclitaxel-coated balloon group, the expression of PI3K/AKT was significantly down-regulated. The use of drug-coated balloons mitigated the cell apoptosis in TUNEL. The expressions of MMP9, TGFβ and IL6 mRNA in the model group were obviously up-regulated; and they were obviously down-regulated in the high-dose gefitinib-coated balloon group compared with the model group.

conclusionsGefitinib-coated balloons were able to suppress the excessive proliferation in the common carotid arterial intima of rats more effectively than the paclitaxel-coated ones. The underlying mechanism may cover the PI3K/AKT signal pathway.

Indexed as

Angioplasty, Balloon, CoronaryCarotid Artery InjuriesCoated Materials, BiocompatibleAnimalsAntineoplastic Agents, PhytogenicApoptosisGefitinibHyperplasiaPaclitaxelPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRandom AllocationRatsRats, Sprague-DawleySignal TransductionVascular System InjuriesAntineoplastic Agents, PhytogenicCoated Materials, BiocompatibleGefitinibPaclitaxelPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktApoptosiscoated balloonsgefitinibpaclitaxelproliferationrestenosis

Identifiers

PMID31045551
PMCPMC6598000
OpenAlexW2942790966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.